Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q3 2022 Earnings Call Transcript

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q3 2022 Earnings Call Transcript November 15, 2022

Inhibikase Therapeutics, Inc. reports earnings inline with expectations. Reported EPS is $-0.18 EPS, expectations were $-0.18.

Operator: Good day, and welcome to Inhibikase Therapeutics’ Third Quarter 2022 Financial Results Conference Call. All participants are in listen-only mode. Please note, this event is being recorded. I would now turn the conference over to Alex Lobo, Stern Investor Relations....